Challenges and limitations of testing efficacy of aerosol device delivery in young children

Jennifer L. Goralski, Stephanie D. Davis

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

An increasing number of medical conditions are chronically or acutely managed with some form of aerosolized therapy. Due to the benefit of directly administering medications to the intended site of action, there is great interest in evaluating treatments for aerosol use. One of the major challenges in selecting and testing new drug-device combinations in children is the uncertainty regarding the appropriate outcome measure to choose. In studies involving adult patients, typically exacerbations of disease or airflow obstruction are assessed as endpoints in drug trials or device assessment. However, in young children, choosing endpoints to assess efficacy is difficult due to the potential lack of sensitive, noninvasive endpoints that are easily performed across sites. In this review, we discuss the challenges and limitations of selecting clinical endpoints for drug-device trials in the youngest population, with a focus on novel emerging technologies. This article provides an overview of preschool and infant pulmonary function testing, multiple-breath washout, imaging techniques including computed tomography and magnetic resonance imaging, flexible bronchoscopy in children, mucociliary clearance scans, and exhaled breath condensate.

Original languageEnglish (US)
Pages (from-to)264-271
Number of pages8
JournalJournal of Aerosol Medicine and Pulmonary Drug Delivery
Volume27
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Aerosols
Equipment and Supplies
Mucociliary Clearance
Bronchoscopy
Drug Combinations
Pharmaceutical Preparations
Uncertainty
Disease Progression
Tomography
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Technology
Lung
Therapeutics
Population

Keywords

  • cystic fibrosis
  • inhaled therapy
  • lung function
  • mucociliary clearance

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Pharmaceutical Science
  • Medicine(all)

Cite this

Challenges and limitations of testing efficacy of aerosol device delivery in young children. / Goralski, Jennifer L.; Davis, Stephanie D.

In: Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 27, No. 4, 01.01.2014, p. 264-271.

Research output: Contribution to journalReview article

@article{33053ad51a744b90b06defb1674e2dd8,
title = "Challenges and limitations of testing efficacy of aerosol device delivery in young children",
abstract = "An increasing number of medical conditions are chronically or acutely managed with some form of aerosolized therapy. Due to the benefit of directly administering medications to the intended site of action, there is great interest in evaluating treatments for aerosol use. One of the major challenges in selecting and testing new drug-device combinations in children is the uncertainty regarding the appropriate outcome measure to choose. In studies involving adult patients, typically exacerbations of disease or airflow obstruction are assessed as endpoints in drug trials or device assessment. However, in young children, choosing endpoints to assess efficacy is difficult due to the potential lack of sensitive, noninvasive endpoints that are easily performed across sites. In this review, we discuss the challenges and limitations of selecting clinical endpoints for drug-device trials in the youngest population, with a focus on novel emerging technologies. This article provides an overview of preschool and infant pulmonary function testing, multiple-breath washout, imaging techniques including computed tomography and magnetic resonance imaging, flexible bronchoscopy in children, mucociliary clearance scans, and exhaled breath condensate.",
keywords = "cystic fibrosis, inhaled therapy, lung function, mucociliary clearance",
author = "Goralski, {Jennifer L.} and Davis, {Stephanie D.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1089/jamp.2013.1097",
language = "English (US)",
volume = "27",
pages = "264--271",
journal = "Journal of Aerosol Medicine and Pulmonary Drug Delivery",
issn = "1941-2711",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Challenges and limitations of testing efficacy of aerosol device delivery in young children

AU - Goralski, Jennifer L.

AU - Davis, Stephanie D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - An increasing number of medical conditions are chronically or acutely managed with some form of aerosolized therapy. Due to the benefit of directly administering medications to the intended site of action, there is great interest in evaluating treatments for aerosol use. One of the major challenges in selecting and testing new drug-device combinations in children is the uncertainty regarding the appropriate outcome measure to choose. In studies involving adult patients, typically exacerbations of disease or airflow obstruction are assessed as endpoints in drug trials or device assessment. However, in young children, choosing endpoints to assess efficacy is difficult due to the potential lack of sensitive, noninvasive endpoints that are easily performed across sites. In this review, we discuss the challenges and limitations of selecting clinical endpoints for drug-device trials in the youngest population, with a focus on novel emerging technologies. This article provides an overview of preschool and infant pulmonary function testing, multiple-breath washout, imaging techniques including computed tomography and magnetic resonance imaging, flexible bronchoscopy in children, mucociliary clearance scans, and exhaled breath condensate.

AB - An increasing number of medical conditions are chronically or acutely managed with some form of aerosolized therapy. Due to the benefit of directly administering medications to the intended site of action, there is great interest in evaluating treatments for aerosol use. One of the major challenges in selecting and testing new drug-device combinations in children is the uncertainty regarding the appropriate outcome measure to choose. In studies involving adult patients, typically exacerbations of disease or airflow obstruction are assessed as endpoints in drug trials or device assessment. However, in young children, choosing endpoints to assess efficacy is difficult due to the potential lack of sensitive, noninvasive endpoints that are easily performed across sites. In this review, we discuss the challenges and limitations of selecting clinical endpoints for drug-device trials in the youngest population, with a focus on novel emerging technologies. This article provides an overview of preschool and infant pulmonary function testing, multiple-breath washout, imaging techniques including computed tomography and magnetic resonance imaging, flexible bronchoscopy in children, mucociliary clearance scans, and exhaled breath condensate.

KW - cystic fibrosis

KW - inhaled therapy

KW - lung function

KW - mucociliary clearance

UR - http://www.scopus.com/inward/record.url?scp=84905488039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905488039&partnerID=8YFLogxK

U2 - 10.1089/jamp.2013.1097

DO - 10.1089/jamp.2013.1097

M3 - Review article

C2 - 24476048

AN - SCOPUS:84905488039

VL - 27

SP - 264

EP - 271

JO - Journal of Aerosol Medicine and Pulmonary Drug Delivery

JF - Journal of Aerosol Medicine and Pulmonary Drug Delivery

SN - 1941-2711

IS - 4

ER -